We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
- Authors
Göksu, Sema Sezgin; Tatlı, Ali Murat; Geredeli, Çağlayan; Atcı, Mustafa; Besen, Ali Ayberk; Mertsoylu, Hüseyin; Uysal, Mükremin; Özdoğan, Mustafa; Aydın, Sabin Göktaş; Bilici, Ahmet; Karaağaç, Mustafa; Artaç, Mehmet; Kaplan, Muhammet Ali; Ebinç, Senar; Coşkun, Hasan Şenol
- Abstract
<bold>Purpose: </bold>In this study, we looked for whether treatment-induced rash predicts treatment efficacy in patients with recurrent/metastatic HNSCC treated with Cetuximab and chemotherapy.<bold>Methods: </bold>Patients who were treated with platinum-based chemotherapy and cetuximab for the first line treatment of recurrent/metastatic HNSCC were recruited. Presence of rash, hypomagnesemia, hypopotassemia, anemia, neutropenia, thrombocytopenia during treatment and treatment response, date of progression, date of last visit and death were recorded.<bold>Results: </bold>A total of 138 patients' data were available for analysis. Any grade of rash was detected in 57 (44.5%) of the patients. The incidence of rash was significantly higher in patients with objective response than in patients with disease progression (%56.8 vs %14.3, p < 0.001). Progression free survival was 7.06 months (4.98-9.15) in patients treated with cetuximab and chemotherapy as first line treatment. In the multivariate analysis; rash was significantly correlated with longer PFS (HR 2.136; 95% CI 1.067-4.278; p = 0.032). Progression free survival was 9.65 months in patients who experienced rash, and 6.02 months in patients without rash, (p = 0.019, log-rank test). Overall survival was 11.24 months (9.65-12.82). In multivariate analysis, the survival of patients with rash was significantly longer than patients without rash (HR 1.954; 95% CI 1.162-3.285; p = 0.012). Overall survival was 15.08 months in patients who experienced rash, and 8.61 months in patients without rash (p = 0.05, log-rank test).<bold>Conclusion: </bold>Cetuximab-induced rash is associated with better ORR and longer PFS and OS in patients with recurrent/metastatic HNSCC treated with Cetuximab and platinum-based chemotherapy.
- Subjects
OVERALL survival; SQUAMOUS cell carcinoma; NECK; PROGRESSION-free survival; LOG-rank test; MULTIVARIATE analysis
- Publication
Cancer Chemotherapy & Pharmacology, 2021, Vol 88, Issue 5, p805
- ISSN
0344-5704
- Publication type
journal article
- DOI
10.1007/s00280-021-04328-9